<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9102">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988440</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001G2101</org_study_id>
    <secondary_id>2016-004131-20</secondary_id>
    <nct_id>NCT02988440</nct_id>
  </id_info>
  <brief_title>Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients</brief_title>
  <official_title>A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two part study to determine the maximum tolerated dose and/or recommended phase 2 dose of
      PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma in
      first line. There will be a dose escalation part and a dose expansion part.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 3, 2017</start_date>
  <completion_date type="Anticipated">July 4, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AEs) as a measure of safety and tolerability</measure>
    <time_frame>continuous until 150 days after last treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Ctrough</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Day one of cycles 3, 4, 6, 8, 10, 12 and Day 1 of every 6th cycle thereafter, end of treatment and 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Cmax</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Day one of cycles 3, 4, 6, 8, 10, 12 and Day 1 of every 6th cycle thereafter, end of treatment and 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): AUC</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Day one of cycles 3, 4, 6, 8, 10, 12 and Day 1 of every 6th cycle thereafter, end of treatment and 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) using RECIST v1.1 criteria)</measure>
    <time_frame>Baseline, every 8 weeks until progression up to 1 year after last patient first treatment</time_frame>
    <description>RECIST v1.1 = Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Baseline, every 8 weeks until progression up to 1 year after last patient first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Baseline, every 8 weeks until progression up to 1 year after last patient first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Baseline, every 8 weeks until progression up to 1 year after last patient first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Baseline, every 8 weeks until progression up to 1 year after last patient first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) per RECIST v1.1</measure>
    <time_frame>Baseline, every 8 weeks until progression up to 1 year after last patient first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Every 3 months after last visit up to 2 year after last patient first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADA) prevalence at baseline and on treatment</measure>
    <time_frame>Day one of cycles 1, 2, 3, 4, 6, 8, 10, 12 and Day 1 of every 6th cycle thereafter, end of treatment and 30 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>PDR001 + Sorafenib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <arm_group_label>PDR001 + Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <arm_group_label>PDR001 + Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced (unresectable and/or metastatic)
             HCC

          -  Patients with advanced HCC not amenable for surgical or loco-regional treatment

          -  At least one measureable tumor lesion that that has not been previously locally

          -  Patients with current cirrhotic status of Child-Pugh class A only (5-6 points with
             total bilirubin &lt; 2 mg/dL for dose-escalation) with no encephalopathy and no clinical
             ascites (ascites controlled by diuretics is also excluded in this study).

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Patient must meet required laboratory values at the screening

          -  Normal electrocardiogram at screening

        Exclusion Criteria:

          -  Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC

          -  Invasion of the main portal vein and/or tumor involvement in more than 50% of the
             liver (applicable only for the dose-escalation part)

          -  Patients with Portal-caval shunts

          -  Prior or concomitant systemic anti-cancer treatment for advanced disease

          -  Systemic chronic steroid therapy (â‰¥ 10mg/day prednisone or equivalent) or any
             immunosuppressive therapy 7 days prior to planned date for first dose of study
             treatment. Topical, inhaled, nasal and ophthalmic steroids are allowed.

          -  Cardiac or cardiac repolarization abnormality

          -  Patients with active Hepatitis B infection (HBsAg positive) that are not receiving
             antiviral treatment are excluded

          -  Patients with positive test for hepatitis C ribonucleic acid (HCV RNA)

          -  Loco-regional treatment within 4 weeks prior to initiation of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>December 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Hepatocellular carcinoma (HCC)</keyword>
  <keyword>PDR001</keyword>
  <keyword>liver cancer</keyword>
  <keyword>immunotherapy liver</keyword>
  <keyword>malignant hepatoma</keyword>
  <keyword>Hepatocellular cancer</keyword>
  <keyword>advanced hepatocellular carcinoma (HCC)</keyword>
  <keyword>advanced liver cancer</keyword>
  <keyword>liver cancer progression</keyword>
  <keyword>sorafenib</keyword>
  <keyword>anti-PD1</keyword>
  <keyword>first line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
